UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000001396 |
|---|---|
| Receipt number | R000001698 |
| Scientific Title | Randomized phase III study of FOLFOX plus bevacizumab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer |
| Date of disclosure of the study information | 2008/09/26 |
| Last modified on | 2016/10/12 14:01:22 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Randomized phase III study of FOLFOX plus bevacizumab versus
FOLFIRI plus bevacizumab for metastatic colorectal cancer
Acronym
Randomized phase III study of bevacizumab containing chemotherapy for metastatic colorectal cancer
Scientific Title
Randomized phase III study of FOLFOX plus bevacizumab versus
FOLFIRI plus bevacizumab for metastatic colorectal cancer
Scientific Title:Acronym
Randomized phase III study of bevacizumab containing chemotherapy for metastatic colorectal cancer
Region
| Japan |
Condition
Condition
metastatic colorectal cancer
Classification by specialty
| Gastroenterology | Hematology and clinical oncology | Gastrointestinal surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To compare combination chemotherapy of bevacizumab plus FOLFOX with combination chemotherapy of bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer.
Basic objectives2
Others
Basic objectives -Others
Progression free survival, Overall survival, Time to treatment failure, Response rate, R0 resection rate, Toxicity, Quality of life
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Phase III
Assessment
Primary outcomes
Progression free survival
Key secondary outcomes
Overall survival, Time to treatment failure, Response rate, R0 resection rate, Toxicity, Quality of life
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Active
Stratification
YES
Dynamic allocation
YES
Institution consideration
Institution is considered as adjustment factor in dynamic allocation.
Blocking
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
FOLFOX plus bevacizumab
Interventions/Control_2
FOLFIRI plus bevacizumab
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 75 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1.Histologically documented metastatic measurable adenocarcinoma of the colorectum with no prior chemotherapies for metastatic disease.
2.Age: >20, <75.
3.ECOG PS of 0 or 1.
4.Adequate hematologic, renal, and hepatic function as defined by required baseline laboratory parameters.
5.Written informed consent.
Key exclusion criteria
1.Brain metastasis with symptoms.
2.Massive asites, pleural effusion or pericardial effusion.
3.Double cancer with in five years prior to enroll in this study.
4.Serious non-healing wound.
5.Major surgical procedure within 28 days prior to enroll in this study.
6.Minor surgical procedure within 14 days prior to enroll in this study.
7.Other serious concomitant disease.
8.Regular use of corticosteroid.
9.Regular use of anticoagulation therapy.
10.Peripheral neuropathy > Grade 1 at baseline.
11.Active infectious disease.
12.History of serious hypersensitivity.
13.Hepatitis B surface antigen.
14.Mental disorder.
15.Pregnant or nursing.
Target sample size
400
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Kentaro Yamazaki |
Organization
Shizuoka Cancer Center
Division name
Division of Gastrointestinal Oncology and Endoscopy
Zip code
Address
1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777 Japan
TEL
055-989-5222
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Shinichiro Nakamura |
Organization
West Japan Oncology Group
Division name
WJOG datacenter
Zip code
Address
Namba Plaza Bldg.3F 1-5-7,Motomachi Naniwa-ku,Osaka556-0016 JAPAN
TEL
06-6633-7400
Homepage URL
datacenter@wjog.jp
Sponsor or person
Institute
West Japan Oncology Group
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
静岡県立静岡がんセンター（静岡県）
兵庫県立淡路病院（兵庫県）
自治医科大学（栃木県）
健生会 土庫病院（奈良県）
宮崎大学附属病院（宮崎県）
独立行政法人国立病院機構 九州がんセンター（福岡県）
九州大学病院（福岡県）
独立行政法人国立病院機構 四国がんセンター（愛媛県）
大阪市立総合医療センター（大阪府）
筑波大学附属病院（茨城県）
KKR札幌医療センター 斗南病院（北海道）
地方独立行政法人大阪府立病院機構 大阪府立成人病センター（大阪府）
栃木県立かんセンター（栃木県）
市立釧路総合病院（北海道）
龍ヶ崎済生会病院（茨城県）
大阪医科大学附属病院（大阪府）
近畿大学医学部堺病院（大阪府）
愛知県がんセンター中央病院（愛知県）
帝京大学医学部付属病院（東京都）
聖マリアンナ医科大学病院（神奈川県）
地方独立行政法人大阪府立病院機構 大阪府立呼吸器・アレルギー医療センター（大阪府）
高知医療センター（高知県）
近畿大学医学部附属病院（大阪府）
近畿大学医学部奈良病院（奈良県）
熊本地域医療センター（熊本県）
札幌医科大学附属病院（北海道）
新潟県立がんセンター新潟病院（新潟県）
富山大学医学部（富山県）
東海大学医学部付属病院（神奈川県）
大阪府立急性期・総合医療センター（大阪府）
横浜市立市民病院（神奈川県）
独立行政法人国立病院機構 北海道がんセンター（北海道）
神戸大学医学部附属病院（兵庫県）
独立行政法人国立病院機構 岡山医療センター（岡山県）
市立吹田市民病院（大阪府）
県立広島病院（広島県）
徳島大学病院（徳島県）
兵庫県立がんセンター（兵庫県）
名古屋共立病院（愛知県）
市立室蘭総合病院（北海道）
群馬大学大学院（群馬県）
済生会宇都宮病院（群馬県）
NTT東日本関東病院（東京都）
倉敷中央病院（岡山県）
愛媛県立中央病院（愛媛県）
亀田総合病院（千葉県）
千葉県がんセンター（千葉県）
癌研究会有明病院（東京都）
名古屋市立大学病院（愛知県）
岡山赤十字病院（岡山県）
Other administrative information
Date of disclosure of the study information
| 2008 | Year | 09 | Month | 26 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
https://www.ncbi.nlm.nih.gov/pubmed/27177863
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2008 | Year | 06 | Month | 27 | Day |
Date of IRB
Anticipated trial start date
| 2008 | Year | 09 | Month | 01 | Day |
Last follow-up date
| 2015 | Year | 02 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2008 | Year | 09 | Month | 26 | Day |
Last modified on
| 2016 | Year | 10 | Month | 12 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001698
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
